Crossmark

Hepatocellular carcinoma in young morbid obese patients with non-alcoholic fatty liver disease

Published Online: 2020-09-02

Published Print: 2020-12

Authors

Tobari, Maki

Hashimoto, Etsuko https://orcid.org/0000-0002-0538-1709
Taniai, Makiko

Nishino, Takayoshi

Tokushige, Katsutoshi
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP19fk0210040.)
License Information

Text and Data Mining valid from 2020-09-02

Version of Record valid from 2020-09-02
More Information

Article History

Received: 16 May 2020

Accepted: 16 August 2020

First Online: 2 September 2020

Compliance with ethical standards

:

: Professor Katsutoshi Tokushige received research funding from Sumitomo Dainippon Pharma; Astellas Pharma; Eisai; TAIHO Pharmaceutical; Chugai Pharmaceutical; Daiichi Sankyo Pharmaceutical; AbbVie GK; Takeda Pharmaceutical Company; Asahi Kasei Corporation; AJINOMOTO; and Otsuka Pharmaceutical. The other authors have no conflicts of interest.

: All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from all patients for being included in the study.

Document is current